



Effect of Oral Synbiotic Consumption on Glycemic Control and Honeymoon Phase Duration in Children with Type 1 Diabetes: A Randomized Clinical Trial

Sara Nikpour^{1,2}, Nosrat Ghaemi^{3,*}, Nasrin Moazzen^{id 4,**}, Sepideh Bagheri³, Samaneh Noroozi Asl³, Hamid Ahanchian^{id 5}, Tahereh Sadeghi^{id 6}

¹ Clinical Research Development Unit of Akbar Hospital, Department of Pediatrics, School of Medicine, Akbar Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

² Pediatric Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran

³ Department of Pediatrics, School of Medicine, Akbar Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

⁴ Department of Pediatrics, School of Medicine, Allergy Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

⁵ Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

⁶ Department of Pediatrics, Nursing and Midwifery Care Research Center, Akbar Hospital, School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran

*Corresponding Author: Department of Pediatrics, School of Medicine, Akbar Hospital, Mashhad University of Medical Sciences, Mashhad, Iran. Email: ghaemin@mums.ac.ir

**Corresponding Author: Department of Pediatrics, School of Medicine, Allergy Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran. Email: moazzen@mums.ac.ir

Received: 10 May, 2025; Revised: 31 May, 2025; Accepted: 10 June, 2025

Abstract

Background: The present study aimed to investigate the effects of synbiotics on glycemic control and the duration of the honeymoon phase in newly diagnosed children with type 1 diabetes mellitus (T1DM).

Methods: This study is a randomized, triple-blind clinical trial conducted in Mashhad in 2023. The samples included children aged 2 to 18 years who were referred to the Endocrinology Clinic of Akbar Children's Hospital. The patients were randomly divided into two groups: Synbiotic and placebo (60 participants in each group). The synbiotic group received capsules containing specific strains of *Lactobacillus*, *Bifidobacterium*, and *Streptococcus thermophilus*, while the placebo group received a placebo for six months. Blood sugar control indices, HbA1c, and lipid profiles were recorded at the beginning of the study and then at three-month intervals. The duration of the honeymoon period and the number of diabetic ketoacidosis attacks during treatment were also examined. Patients were followed up every three months for one year. Data were analyzed using SPSS version 22 software, and a 95% confidence level was considered.

Results: After six months, the synbiotic group showed a significant decrease in total daily insulin dose compared to the placebo group ($P = 0.000$). No significant differences were observed in mean HbA1c levels between the two groups before the study and three months after synbiotic consumption ($P > 0.05$). However, after the six-month follow-up, the synbiotic group demonstrated a significant decrease in HbA1c levels ($P = 0.039$). At the end of the six months, the percentage of participants in the honeymoon phase differed significantly between the two groups, with 3.3% in the placebo group and 13.3% in the synbiotic group ($P = 0.048$).

Conclusions: Synbiotic supplementation in children with T1DM can lead to improvements in glycemic control, including reduced insulin requirements, enhanced HbA1c levels, and a prolonged honeymoon phase. These outcomes highlight the potential of synbiotics as a supportive adjunct to standard diabetes management strategies for improving glycemic control in this population.

Keywords: Diabetes Mellitus, Synbiotics, Children

1. Background

Type 1 diabetes mellitus (T1DM) is a prevalent chronic disease among the pediatric population, significantly impacting their lives (1, 2). It ranks as the second most common autoimmune disease in children and is associated with substantial mortality and morbidity throughout their lifespan (3). The incidence of T1DM varies across different regions of the world, but there has been a global increase in its occurrence (4, 5). In

2021, approximately 355,900 new cases of type 1 diabetes were reported globally among children and adolescents, with varying levels of underdiagnosis depending on the region. By 2050, the projected number of incident childhood cases is estimated to rise to 476,700 (6).

Type 1 diabetes mellitus is characterized by low or absent endogenous insulin levels, necessitating lifelong insulin administration and continuous monitoring of blood sugar levels (5). The acute and long-term complications associated with T1DM, such as

hypoglycemia, diabetic ketoacidosis, and various organ complications, considerably impact morbidity and mortality rates in pediatric patients (7, 8). These complications also impose a significant burden on healthcare services and result in increased healthcare costs (9).

While the exact cause of T1DM remains incompletely understood, research has shed light on its multifactorial etiology involving genetic, environmental, chemical-induced, or infectious factors (5, 8, 10). The destruction of beta cells and impaired glucose utilization are central to the disease's pathogenesis (8). Consequently, ongoing investigations focus on interventions aimed at preserving or regenerating beta cells to achieve a less severe disease course and potential cure (4, 8).

In recent years, there has been increasing recognition of the influence of viral infections, the hygiene hypothesis, and alterations in the gut microbiome in the development and progression of T1DM (8, 11). Notably, gastrointestinal bacteria play a crucial role in the development of T1DM by influencing the function of the intestinal mucosa and promoting autoimmunity against pancreatic beta cells. Disturbance of the intestinal bacterial flora significantly impacts glucose, lipid, and insulin metabolism, leading to the onset of metabolic syndrome, insulin resistance, and diabetes (3). Emerging evidence indicates disparities in the composition of intestinal bacteria between individuals with and without diabetes, characterized by a reduction in strains belonging to the phylum *Firmicutes* and *Clostridia*, accompanied by a rise in *Bacteroidetes* and *Proteobacteria* strains (12).

Following the onset of T1DM in pediatric patients, a honeymoon phase ensues, characterized by partial remission, preserved beta cell function, and decreased insulin requirements (13). There is no consensus on the clinical definition of the honeymoon phase, but it could be defined as an insulin requirement of less than 0.5 units/kg/day, accompanied by an HbA1c level below 7% (14). The honeymoon phase, spanning between 7 and 9 months, is considered crucial in the early management of diabetes (15). It reveals optimal efficacy in introducing novel dietary patterns, immunotherapies, and strategies aimed at preserving and/or expanding β -cell mass (15). Predictors of a prolonged honeymoon phase include older age at onset, male gender, absence of ketoacidosis, and minimal metabolic disturbance at diagnosis (16, 17). Various interventions have been proposed to extend or enhance this phase, but their impact on residual beta cell functioning remains inconclusive (14, 15).

In recent years, the potential use of synbiotics in managing diabetes, including type 1 diabetes, has been investigated (8, 18, 19). Notably, a systematic review has demonstrated the potential therapeutic value of synbiotics in diabetes management (19). Although promising effects have been observed in animal studies, further research is needed to validate these findings in human trials (19).

2. Objectives

Therefore, given the affordability, safety, and accessibility of synbiotics, we aimed to evaluate the impact of oral synbiotics on glycemic control and the duration of the honeymoon phase in newly diagnosed children with T1DM. The findings of this research will contribute to ongoing efforts aimed at improving the management and long-term outcomes in pediatric diabetes care.

3. Methods

3.1. Study Design and Settings

This study was conducted as a parallel-group, triple-blind, randomized controlled trial at the outpatient clinic of Akbar Hospital, a tertiary medical center located in Mashhad, Iran, between March 2022 and March 2023.

3.2. Study Population

Children aged 6 to 18 years with newly diagnosed type 1 diabetes, who provided informed consent and were committed to maintaining medication adherence throughout the study, were eligible. Children with coexisting conditions such as significant cardiac, hepatic, or renal diseases, immunodeficiency, allergies to synbiotics, and unwillingness to continue participating in the study were excluded. The diagnosis of T1DM was established based on the criteria outlined by the International Society for Pediatric and Adolescent Diabetes (ISPAD) (20). During the course of the study, a total of 10 individuals were excluded. Within the synbiotic group, five individuals were excluded due to irregular medication intake. In the control group, two individuals did not attend follow-up visits, and three individuals were excluded due to irregular medication intake (Figure 1).

3.3. Ethical Considerations

The research project was approved by the Ethics Committee of Mashhad University of Medical Sciences.




Figure 1. Flow diagram of the randomized study

All methods were conducted following the Declaration of Helsinki. The participants or their guardians provided their written informed consent to participate in the study (IRCT20200117046164N3).

3.4. Study Procedure

3.4.1. Randomization

A simple randomization was carried out on an individual basis using Rand List software. The allocation was performed by an independent monitor and remained blinded until the end of the study. Patients were randomly assigned to the synbiotic or placebo group in a 1:1 ratio. The random allocation to the two groups was done using a 4-block design [AABB (1), ABAB

(2), ABBA (3), BBAA (4), BABA (5), BAAB (6)]. The list of blocks was written and assigned numbers, and random numbers between 1 and 6 were selected using the website

<http://www.graphpad.com/quickcalcs/index.cfm>. The treatment allocation list was determined based on the previous random numbers (...AABB-BBAA-BABA-).

3.4.2. Blinding

The researchers were blinded to group assignments throughout the study. The synbiotic capsules were given randomized codes, and clinicians blindly administered them to participants in the synbiotic and placebo groups. Data collection and analysis were also performed blindly. All follow-up data were collected by two researchers who were blinded to group

Table 1. Comparison of the Demographic Characteristics of Patients in the Synbiotic and Placebo Groups^a

Variables	Synbiotic Group (n = 60)	Placebo Group (n = 60)	P-Value
Age	9.48 ± 2.31	9.28 ± 2.61	0.658
Weight (kg)	31.14 ± 10.94	29.94 ± 10.70	0.545
Height (cm)	134.10 ± 14.07	131.64 ± 14.63	0.353
Sex			0.100
Female	25 (41.7)	34 (56.7)	
Male	35 (58.3)	26 (43.3)	
Percentile			0.646
Under weight	12 (20.0)	14 (23.7)	
Normal weight	41 (68.3)	38 (64.4)	
Over weight	6 (10.0)	4 (6.8)	
Obese	1 (1.7)	3 (2.5)	

^a Values are expressed as No. (%) or mean ± SD.

Table 2. Comparison of Short-Acting and Long-Acting Insulin Levels in the Synbiotic and Placebo Groups^a

Variables	Synbiotic Group (n = 60)	Placebo Group (n = 60)	P-Value
Short-acting insulin			
Pre-intervention short-acting insulin	11.40 ± 5.01	13.08 ± 4.60	0.058
Post-intervention short-acting insulin (3 mon)	11.00 ± 5.22	13.05 ± 4.60	0.025
Post-intervention short-acting insulin (6 mon)	9.62 ± 5.10	12.77 ± 4.70	0.001
Post-intervention short-acting insulin (9 mon)	9.72 ± 5.30	12.40 ± 4.8	0.013
Post-intervention short-acting insulin (12 mon)	9.81 ± 5.35	12.55 ± 4.96	0.013
Long-acting insulin			
Pre-intervention long-acting insulin	9.45 ± 4.37	9.85 ± 5.05	0.644
Post-intervention long-acting insulin (3 mon)	9.30 ± 4.56	9.55 ± 5.39	0.785
Post-intervention long-acting insulin (6 mon)	8.28 ± 4.85	10.67 ± 5.65	0.015
Post-intervention long-acting insulin (9 mon)	8.56 ± 5.06	10.73 ± 6.04	0.064
Post-intervention long-acting insulin (12 mon)	8.57 ± 5.06	10.77 ± 6.09	0.062

^a Values are expressed as mean ± SD.

assignments. The researchers who generated the randomization sequence were not involved in the treatment or future evaluation of the participants.

3.4.3. Study Interventions

In the synbiotic group, newly diagnosed children with T1DM aged 6 to 18 years received synbiotics for six months. The synbiotics were supplied in the form of capsules by ZIST TAKHMIR Company, Iran, containing the strains *Lactobacillus rhamnosus*, *L. casei*, *L. bulgaricus*, *L. acidophilus*, *Bifidobacterium breve*, *B. longum*, and *Streptococcus thermophiles* at a concentration of 10⁹ CFU. The product also contained fructooligosaccharides (FOS) as a placebo and was gluten-free. In the placebo group, newly diagnosed children with T1DM aged 6 to 18 years received a placebo for six months. The placebo was

similar in taste and appearance to the active product and also contained FOS as a placebo. The placebo did not contain synbiotics and was gluten-free.

3.4.4. Monitoring of the Study Participants

Participants were monitored at three-month intervals for six months. During each visit, glycemic control and the total daily insulin dose required to maintain optimal glycemic control were evaluated and recorded.

3.4.5. Outcome Measures

The main outcome variables of the study included the total daily insulin dose and HbA1c levels. Secondary measures included insulin requirements (unit/kg/day),

Table 3. Comparison of Insulin Levels Based on Weight in the Synbiotic and Placebo Groups ^a

Variables	Synbiotic Group (n = 60)	Placebo Group (n = 60)	P-Value
Pre-intervention total daily dose of insulin/kg	0.69 ± 0.25	0.78 ± 0.25	0.049
Post-intervention total daily dose insulin/kg (3 mon)	0.63 ± 0.27	0.83 ± 0.28	0.000
Post-intervention total daily dose insulin/kg (6 mon)	0.59 ± 0.27	0.81 ± 0.27	0.000
Post-intervention total daily dose insulin/kg (9 mon)	0.61 ± 0.31	0.80 ± 0.25	0.002
Post-intervention total daily dose insulin/kg (12 mon)	0.60 ± 0.31	0.80 ± 0.25	0.002

^a Values are expressed as mean ± SD.

the occurrence of concomitant autoimmune diseases (such as celiac disease and Hashimoto's thyroiditis), and complications such as hypoglycemia or diabetic ketoacidosis during the study period. The measurements were obtained by asking the patient and based on prescribed insulin for glycemic control.

3.5. Statistical Analysis

Based on an attrition rate of 20%, a sample size of 50 individuals per group was determined, resulting in a calculated total sample size of 60 for each group. The formula used to calculate the sample size was *t*-tests - means: Difference between two independent means (two groups), where a confidence level of 95% was considered, with α set at 0.05 and the critical value, $Z_{\alpha/2}$, as 1.96. The values of Z_{β} , representing the critical value of the normal distribution at β (e.g., 1.28 for a power of 90%), and σ^2 , denoting the population variance, were also taken into account. The aim was to detect a specific difference, represented by d . For this study, a total of 130 individuals were initially included in the sample. However, 10 individuals were subsequently excluded during the sampling process. Out of these exclusions, 5 individuals from the synbiotic group were excluded due to irregular medication consumption, while in the control group, 2 individuals were excluded due to non-attendance, and 3 individuals were excluded due to irregular medication consumption.

Data were analyzed using SPSS version 22.0. Descriptive statistics, including mean, standard deviation, and frequency distribution, were used to describe the participants' characteristics. The distribution normality of quantitative variables was tested using the Kolmogorov-Smirnov test. The homogeneity of the two groups in terms of underlying and confounding variables was assessed using the chi-square test and independent *t*-tests. Between-group comparisons were performed using independent *t*-tests, while within-group comparisons were conducted using

paired *t*-tests to achieve the main objectives of the study. For all parameters, the P-value was set at 0.05.

4. Results

A total of 120 patients with T1DM were enrolled in this study. There were no statistically significant differences in mean age, duration of illness, and BMI percentile between the synbiotic and placebo groups (Table 1). The mean pre-intervention insulin dose was 11.40 ± 5.01 in the synbiotic group and 12.88 ± 4.90 in the placebo group. No significant difference was found in the mean insulin dose between the two groups ($P > 0.05$). However, after six months of follow-up, the mean long-acting insulin dose was 9.45 ± 4.37 in the synbiotic group and 9.85 ± 5.05 in the placebo group. There was no significant difference observed in the mean long-acting insulin dose between the two groups before the intervention and three months after the study ($P > 0.05$). However, after six months of follow-up, the synbiotic group demonstrated a significant reduction in long-acting insulin levels ($P < 0.05$) (Table 2).

The total daily insulin dose did not significantly differ between the patients before the study (Table 3). Nevertheless, after six months of follow-up, the insulin intake in the synbiotic group dropped significantly ($P < 0.05$) (Figure 2). The mean pre-intervention HbA1c levels were 12.18 ± 2.33 in the synbiotic group and 11.48 ± 2.73 in the placebo group. There were no significant differences in mean HbA1c levels between the two groups before the study and three months after synbiotic consumption ($P > 0.05$) (Table 4). After six months and 12 months of follow-up, HbA1c levels in the synbiotic group showed a significant decrease ($P < 0.05$) (Figure 3).

The mean HbA1c level before intervention in the synbiotic group was 12.18 ± 2.33 and in the placebo group was 11.48 ± 2.73 . The two groups did not differ significantly in terms of mean HbA1c levels before the study and three months after synbiotic consumption ($P > 0.05$). After 6, 9, and 12 months of follow-up, the HbA1c levels of patients in the synbiotic group decreased, and




Figure 2. Comparison of the total daily insulin dose in the synbiotic and placebo groups

this decrease was statistically significant ($P < 0.05$). In the placebo group, 3.3% of the participants were in the honeymoon phase, while 13.3% of participants in the synbiotic group were in the honeymoon phase at the end of six months, and at the end of the twelfth month, 8.5% remained in this period (Table 5).

At the end of one year of follow-up, the C-peptide level in the patients' blood was measured. There was no statistically significant difference in the percentage of C-peptide above 0.7 in the patients of the two groups. The mean serum C-peptide level was also measured in the two groups. It was reported as 0.13 ± 0.199 in the synbiotic group and 0.22 ± 0.24 in the placebo group. There was no statistically significant difference in the mean C-peptide level between the two groups (Table 6).

5. Discussion


This study presents a randomized, triple-blind clinical trial aimed at assessing the effect of synbiotics on glycemic control and the duration of the honeymoon phase among pediatric patients with T1DM in Iran. A comparison of the synbiotic and placebo

groups in terms of the average amount of short-acting insulin showed that at the beginning of the study, the two groups did not differ significantly. However, after follow-ups at 6, 9, and 12 months, the amount of short-acting insulin in the synbiotic group decreased significantly. The two groups did not differ significantly in terms of the average amount of long-acting insulin before the intervention and three months after the start of the intervention. After six months of follow-up, the amount of long-acting insulin in the synbiotic group showed a statistically significant decrease. The daily dose of insulin received was also not significantly different in the patients before the study, but after six months of follow-up, the amount of insulin received in the synbiotic group patients decreased significantly. In the follow-ups of the ninth and twelfth months, although the amount of insulin received decreased, this decrease was not statistically significant.

The comparison of the mean daily total insulin dose based on weight in the synbiotic and placebo groups also showed that although there was no significant difference before the study, after follow-up at 6, 9, and 12 months, the amount of insulin received by patients in

Table 4. Comparison of HbA1C Levels in the Synbiotic and Placebo Groups^a

Variables	Synbiotic Group (n = 60)	Placebo Group (n = 60)	P-Value
Pre- intervention HbA1C	12.18 ± 2.33	11.48 ± 2.73	0.136
Post-intervention HbA1C (3 mon)	9.55 ± 1.54	9.35 ± 1.62	0.491
Post-intervention HbA1C (6 mon)	8.90 ± 1.76	9.54 ± 1.56	0.039
Post-intervention HbA1C (9 mon)	8.66 ± 1.44	9.25 ± 1.34	0.049
Post-intervention HbA1C (12 mon)	8.65 ± 1.46	9.26 ± 1.37	0.045

^a Values are expressed as mean ± SD.**Figure 3.** Comparison of HbA1C levels in the synbiotic and placebo groups

the synbiotic group decreased significantly. The two groups were also compared in terms of mean HbA1c. The results showed that the two groups did not differ significantly in terms of mean HbA1c before the intervention and three months after synbiotic consumption, but after follow-up at 6, 9, and 12 months, the HbA1c levels of patients in the synbiotic group decreased significantly. These results are consistent with the findings of Ejtehad et al. (21), who found that the consumption of synbiotic yogurt significantly reduced fasting blood glucose and HbA1c levels among patients with type 2 diabetes. Similarly, Andreasen et al. (22)

conducted a study on patients with type 2 diabetes and observed that a four-week treatment with the synbiotic strain *L. acidophilus* NCFM improved insulin sensitivity compared to a placebo.

These findings suggest that synbiotics hold promise as an agent for diabetes management. Our study aligns with previous research (23, 24) that supports the positive impact of synbiotics on glycemic control, thereby strengthening the hypothesis that gut dysbiosis contributes to the pathogenesis of T1DM. In children with T1DM, the gut microbiome composition displays an

Table 5. Comparison of the Honeymoon Phase in the Synbiotic and Placebo Groups ^a

Variables	Placebo Group	Synbiotic Group	P-Value
The honeymoon phase at the time of diagnosis	5 (8.3)	9 (15.0)	0.255
Honeymoon phase (6 mon)	2 (3.3)	8 (13.3)	0.048
Honeymoon phase (12 mon)	2 (4.7)	4 (8.5)	0.463

^a Values are expressed as No. (%).

Table 6. Comparison of C-peptide Test in Patients with Type 1 Diabetes in the Two Synbiotic and Placebo Groups ^a

Variables	Placebo Group	Synbiotic Group	P-Value
C-peptide test < 0.7	45 (95.7)	41 (93.5)	0.927 ^b
C-peptide test > 0.7	2 (4.3)	2 (4.7)	
C-peptide level	0.13 ± 0.199	0.22 ± 0.24	0.087 ^c

^a Values are expressed as No. (%) or mean ± SD.

^b Fisher's exact test.

^c Independent samples test.

elevation in virulence factors, phage, prophage, and motility genes. They also have a lower count of bacteria that produce butyrate, a type of short-chain fatty acid (SCFA) known for its anti-inflammatory actions (25).

Importantly, despite the observed benefits, it is critical to consider potential confounders that may have influenced our outcomes. Variables such as baseline dietary intake, level of physical activity, socioeconomic background, genetic susceptibility, medication adherence, and the initial composition of the gut microbiota could all serve as confounding factors. These elements were not fully evaluated or adjusted for in this trial, which may have introduced bias in interpreting the true effect of synbiotics. Additional factors such as psychosocial stress, pubertal status, or concurrent infections might also have influenced insulin requirements and glycemic control. Future research should address these confounders through stratification or multivariate regression models to better isolate the impact of synbiotic interventions.

Furthermore, deeper exploration into mechanistic pathways is needed to elucidate how synbiotics might modulate glycemic outcomes. Current hypotheses include modulation of the gut microbiome to favor butyrate-producing bacteria, improvement of mucosal immunity and intestinal barrier integrity, anti-inflammatory effects through downregulation of Toll-like receptor (TLR) signaling, and enhancement of glucagon-like peptide-1 (GLP-1) secretion. Synbiotics may also affect bile acid metabolism and microbial metabolite production, contributing to improved

insulin sensitivity. Experimental studies in animal models support these mechanisms by showing preserved β -cell integrity, reduced oxidative stress, and mitigation of hyperglycemia. Hence, investigating inflammatory markers, gut microbiome profiles, SCFA levels, and incretin hormones in future clinical trials may provide deeper mechanistic insight and support causality in observed clinical outcomes.

However, the precise mechanism through which synbiotics improve the glycemic profile remains unclear (19, 23). The underlying mechanisms suggested regarding the potential of synbiotics to prevent or delay the onset of T1DM include the augmentation of GLP-1 secretion to enhance carbohydrate metabolism, reduction of glucotoxicity, improvement in intestinal epithelium integrity, inhibition of the TLR pathway, attenuation of pro-inflammatory signaling, enhancement of insulin sensitivity, and consequent alterations in gene expression (23, 25). Animal experiments suggest that synbiotics reveal inhibitory effects against insulin depletion and nitrite formation, leading to the suppression of streptozotocin-induced diabetes. Furthermore, by protecting pancreatic β -cells from damage, synbiotics have the potential to delay STZ-induced alterations in glucose homeostasis by sustaining insulin levels. Additionally, synbiotics, when combined with skim milk, can enhance insulin resistance in the skeletal muscles and adipose tissues of rats subjected to a high-fructose diet, ultimately resulting in declined fasting plasma glucose (FPG) levels (19, 26, 27).

However, although Asemi et al. (25) observed a preventive effect on the elevation of FPG levels, they found no significant beneficial effect on glycemic control in diabetic patients who received multispecies synbiotic supplements. This may be linked to a notable elevation in serum insulin levels. Nevertheless, when compared to the control group, these effects were relatively less pronounced. Notably, the duration of the treatment period appears to play a more crucial role in effectiveness than the dosage of administration. In our study, although no significant difference in HbA1c levels was observed between the two groups before the study and three months after synbiotic consumption, HbA1c levels in the synbiotic group showed a significant reduction after six months. The observed disparities between our results and previous research can be attributed to several factors, including variations in the selection of synbiotics, differences in study design, and potentially the distinct characteristics of the subjects involved. Further research is warranted to establish a comprehensive understanding of the effect of synbiotic supplements on glycemic control in pediatric patients with T1DM.

In our study, the honeymoon period was defined as a total daily insulin dose of less than 0.5 units/kg and an HbA1c of less than 7%. Accordingly, the duration of this period was compared in the two groups. In the placebo group, 8.3% of patients were in the honeymoon period at the time of diagnosis, 3.3% at the end of six months, and 4.7% at the end of the twelfth month. In the synbiotic group, 15% of patients were in the honeymoon period at the beginning. In the sixth month, 13.3% remained in this period, and at the end of the twelfth month, 8.5% remained in this period. Therefore, a longer remission period was observed in the synbiotic group patients. The prevalence of the remission phase in patients with T1DM varies significantly, ranging from 30% to 80% (14, 15). The observed phenomenon of a significant proportion of children entering the honeymoon phase suggests the persistence of β -cell function despite the initiation of insulin treatment. Furthermore, it indicates an inherent attempt at islet regeneration within favorable immunomodulatory conditions (14). In our study, more children in the synbiotic group achieved a honeymoon phase compared to the placebo group, which aligns with Kumar et al.'s findings indicating higher remission rates in the synbiotic group (26.6%) compared to the placebo group (8.8%) over three months (23). However, the mechanism behind this improvement in remission rates remains unknown. Further research is necessary to elucidate these mechanisms and to fully understand the

potential of synbiotic supplements for pediatric T1DM management.

Our study possesses a significant strength as it was designed as a randomized, triple-blind, placebo-controlled study. However, it is important to acknowledge some limitations within this study. Firstly, due to temporal restrictions, the follow-up period for patients was confined to a duration of six months. Secondly, the feasibility of exploring anthropometric factors was restricted.

5.1. Conclusions

The findings of our study demonstrate that the consumption of synbiotics, as compared to a placebo, over six months in newly diagnosed children with T1DM, can result in a significant reduction in insulin requirements, an enhancement in HbA1c levels, and the prolongation of the honeymoon phase. This suggests that synbiotics may have a supportive role in improving glycemic control in these children and can be utilized alongside other diabetes control treatments. However, further studies with a prolonged intervention duration are necessary to evaluate the enduring effects of synbiotics over time. Additionally, investigating the effect of synbiotic supplementation on other biomarkers associated with beta-cell damage in T1DM is essential for comprehending the mechanistic basis for the favorable glycemic effects of synbiotics.

Acknowledgements

The authors express their gratitude to the participants and their parents for their invaluable time and dedication in taking part in this study. Furthermore, the authors extend their appreciation to the dedicated staff at the Pediatrics Endocrinology Department of Akbar Hospital for their support throughout the research process. It is worth mentioning that AI technology was utilized to enhance the language and readability of this paper.

Footnotes

Authors' Contribution: The present study was conceptualized and designed by N. M. and S. B. N. Gh. was responsible for the execution of the study, including participant recruitment. The data analysis and manuscript writing were carried out by T. S. and S. N. S. N. contributed to the study by conducting participant recruitment, preparing test meals, and collecting data, as well as actively engaging in manuscript writing.

Additionally, H. A. played a role in the study's conception and design, manuscript writing, and manuscript revision. All authors thoroughly reviewed and provided their approval for the final manuscript.

Clinical Trial Registration Code: [IRCT20200117046164N3](https://www.clinicaltrials.gov/study/NCT02020011).

Conflict of Interests Statement: The authors declare no conflict of interests.

Data Availability: The data that support the findings of this study are available from the corresponding author upon request.

Ethical Approval: The present study was approved by the Research Ethics Committee at Mashhad University of Medical Sciences ([IR.MUMS.MEDICAL.REC.1400.800](https://www.mums.ac.ir)).

Funding/Support: The present study received no funding/support.

Informed Consent: A written informed consent was obtained from each study participant and their parents.

References

- Lora ALM, Espindola ME, Paz MB, Díaz JMM, Klünder MK. Diabetes in Children and Adolescents. In: Rodriguez-Saldana J, editor. *The Diabetes Textbook: Clinical Principles, Patient Management and Public Health Issues*. Cham, Germany: Springer International Publishing; 2023. p. 1063-94. https://doi.org/10.1007/978-3-031-25519-9_64.
- Los E, Wilt AS. *Type 1 Diabetes in Children*. Treasure Island (FL): StatPearls; 2025.
- Shabani-Mirzaee H, Haghshenas Z, Malekiantaghi A, Vigh M, Mahdavi F, Eftekhari K. The effect of oral probiotics on glycated haemoglobin levels in children with type 1 diabetes mellitus - a randomized clinical trial. *Pediatr Endocrinol Diabetes Metab*. 2023;**29**(3):128-33. [PubMed ID: [38031828](https://pubmed.ncbi.nlm.nih.gov/38031828/)]. [PubMed Central ID: [PMC10679923](https://pubmed.ncbi.nlm.nih.gov/PMC10679923/)]. <https://doi.org/10.5114/pedm.2023.132025>.
- Ogle GD, James S, Dabelea D, Pihoker C, Svensson J, Maniam J, et al. Global estimates of incidence of type 1 diabetes in children and adolescents: Results from the International Diabetes Federation Atlas, 10th edition. *Diabetes Res Clin Pract*. 2022;**183**:109083. [PubMed ID: [34883188](https://pubmed.ncbi.nlm.nih.gov/34883188/)]. <https://doi.org/10.1016/j.diabres.2021.109083>.
- Pasi R, Ravi KS. Type 1 diabetes mellitus in pediatric age group: A rising endemic. *J Family Med Prim Care*. 2022;**11**(1):27-31. [PubMed ID: [35309606](https://pubmed.ncbi.nlm.nih.gov/35309606/)]. [PubMed Central ID: [PMC8930152](https://pubmed.ncbi.nlm.nih.gov/PMC8930152/)]. https://doi.org/10.4103/jfmpc.jfmpc_975_21.
- Ward ZJ, Yeh JM, Reddy CL, Gomber A, Ross C, Rittiphairoj T, et al. Estimating the total incidence of type 1 diabetes in children and adolescents aged 0-19 years from 1990 to 2050: a global simulation-based analysis. *Lancet Diabetes Endocrinol*. 2022;**10**(12):848-58. [PubMed ID: [36372070](https://pubmed.ncbi.nlm.nih.gov/36372070/)]. [https://doi.org/10.1016/S2213-8587\(22\)00276-5](https://doi.org/10.1016/S2213-8587(22)00276-5).
- Imperatore G, Mayer-Davis EJ, Orchard TJ, Zhong VW, Cowie CC, Casagrande SS, Menke A, Cissell MA, Eberhardt MS, Meigs JB, et al., editors. *Prevalence and Incidence of Type 1 Diabetes Among Children and Adults in the United States and Comparison With Non-U.S. Countries*. 3rd ed. Bethesda (MD): Diabetes in America; 2018.
- Mameli C, Triolo TM, Chiarelli F, Rewers M, Zuccotti G, Simmons KM. Lessons and gaps in the prediction and prevention of type 1 diabetes. *Pharmacol Res*. 2023;**193**:106792. [PubMed ID: [37201589](https://pubmed.ncbi.nlm.nih.gov/37201589/)]. <https://doi.org/10.1016/j.phrs.2023.106792>.
- Garrett C, Doherty A. Diabetes and mental health. *Clin Med (Lond)*. 2014;**14**(6):669-72. [PubMed ID: [25468856](https://pubmed.ncbi.nlm.nih.gov/25468856/)]. [PubMed Central ID: [PMC4954143](https://pubmed.ncbi.nlm.nih.gov/PMC4954143/)]. <https://doi.org/10.7861/clinmedicine.14-6-669>.
- Murri M, Leiva I, Gomez-Zumaquero JM, Tinahones FJ, Cardona F, Soriguer F, et al. Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study. *BMC Med*. 2013;**11**:46. [PubMed ID: [23433344](https://pubmed.ncbi.nlm.nih.gov/23433344/)]. [PubMed Central ID: [PMC3621820](https://pubmed.ncbi.nlm.nih.gov/PMC3621820/)]. <https://doi.org/10.1186/1741-7015-11-46>.
- Ismail HM, Spall M, Evans-Molina C, DiMeglio LA. Evaluating the effect of prebiotics on the gut microbiome profile and beta cell function in youth with newly diagnosed type 1 diabetes: protocol of a pilot randomized controlled trial. *Pilot Feasibility Stud*. 2023;**9**(1):150. [PubMed ID: [37626387](https://pubmed.ncbi.nlm.nih.gov/37626387/)]. [PubMed Central ID: [PMC10463339](https://pubmed.ncbi.nlm.nih.gov/PMC10463339/)]. <https://doi.org/10.1186/s40814-023-01373-4>.
- Moffa S, Mezza T, Cefalo CMA, Cinti F, Impronta F, Sorice GP, et al. The Interplay between Immune System and Microbiota in Diabetes. *Mediators Inflamm*. 2019;**2019**:9367404. [PubMed ID: [32082078](https://pubmed.ncbi.nlm.nih.gov/32082078/)]. [PubMed Central ID: [PMC7012204](https://pubmed.ncbi.nlm.nih.gov/PMC7012204/)]. <https://doi.org/10.1155/2019/9367404>.
- Passanisi S, Salzano G, Gasbarro A, Urzi Brancati V, Mondio M, Pajno GB, et al. Influence of Age on Partial Clinical Remission among Children with Newly Diagnosed Type 1 Diabetes. *Int J Environ Res Public Health*. 2020;**17**(13). [PubMed ID: [32635304](https://pubmed.ncbi.nlm.nih.gov/32635304/)]. [PubMed Central ID: [PMC7369868](https://pubmed.ncbi.nlm.nih.gov/PMC7369868/)]. <https://doi.org/10.3390/ijerph17134801>.
- Fonolleda M, Murillo M, Vazquez F, Bel J, Vives-Pi M. Remission Phase in Paediatric Type 1 Diabetes: New Understanding and Emerging Biomarkers. *Horm Res Paediatr*. 2017;**88**(5):307-15. [PubMed ID: [28772271](https://pubmed.ncbi.nlm.nih.gov/28772271/)]. <https://doi.org/10.1159/000479030>.
- Nielsens N, Polle O, Robert A, Lysy PA. Integration of Routine Parameters of Glycemic Variability in a Simple Screening Method for Partial Remission in Children with Type 1 Diabetes. *J Diabetes Res*. 2018;**2018**:5936360. [PubMed ID: [29568778](https://pubmed.ncbi.nlm.nih.gov/29568778/)]. [PubMed Central ID: [PMC5822787](https://pubmed.ncbi.nlm.nih.gov/PMC5822787/)]. <https://doi.org/10.1155/2018/5936360>.
- Moole H, Moole V, Mamidipalli A, Dharmapuri S, Boddireddy R, Taneja D, et al. Spontaneous complete remission of type 1 diabetes mellitus in an adult - review and case report. *J Community Hosp Intern Med Perspect*. 2015;**5**(5):28709. [PubMed ID: [26486109](https://pubmed.ncbi.nlm.nih.gov/26486109/)]. [PubMed Central ID: [PMC4612476](https://pubmed.ncbi.nlm.nih.gov/PMC4612476/)]. <https://doi.org/10.3402/jchimp.v5.28709>.
- Yazidi M, Mahjoubi S, Oueslati I, Chaker F, Chihaoui M. The remission phase in adolescents and young adults with newly diagnosed type 1 diabetes mellitus: prevalence, predicting factors and glycemic control during follow-up. *Arch Endocrinol Metab*. 2022;**66**(2):222-8. [PubMed ID: [35315990](https://pubmed.ncbi.nlm.nih.gov/35315990/)]. [PubMed Central ID: [PMC9832884](https://pubmed.ncbi.nlm.nih.gov/PMC9832884/)]. <https://doi.org/10.20945/2359-3997000000456>.
- Pan J, Pan Q, Chen Y, Zhang H, Zheng X. Efficacy of probiotic supplement for gestational diabetes mellitus: a systematic review and meta-analysis. *J Matern Fetal Neonatal Med*. 2019;**32**(2):317-23. [PubMed ID: [28927313](https://pubmed.ncbi.nlm.nih.gov/28927313/)]. <https://doi.org/10.1080/14767058.2017.1376318>.
- Razmpoosh E, Javadi M, Ejtahed HS, Mirmiran P. Probiotics as beneficial agents in the management of diabetes mellitus: a systematic review. *Diabetes Metab Res Rev*. 2016;**32**(2):143-68. [PubMed ID: [25963407](https://pubmed.ncbi.nlm.nih.gov/25963407/)]. <https://doi.org/10.1002/dmrr.2665>.
- Mayer-Davis EJ, Kahkoska AR, Jefferies C, Dabelea D, Balde N, Gong CX, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Definition, epidemiology, and classification of diabetes in children and adolescents. *Pediatr Diabetes*. 2018;**19** Suppl 27(Suppl 27):7-19. [PubMed ID: [30226024](https://pubmed.ncbi.nlm.nih.gov/30226024/)]. [PubMed Central ID: [PMC7521365](https://pubmed.ncbi.nlm.nih.gov/PMC7521365/)]. <https://doi.org/10.1111/pedi.12773>.
- Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid V. Probiotic yogurt improves antioxidant status in type 2 diabetic patients. *Nutrition*. 2012;**28**(5):539-43. [PubMed ID: [22129852](https://pubmed.ncbi.nlm.nih.gov/22129852/)]. <https://doi.org/10.1016/j.nut.2011.08.013>.

22. Andreasen AS, Larsen N, Pedersen-Skovsgaard T, Berg RM, Moller K, Svendsen KD, et al. Effects of *Lactobacillus acidophilus* NCFM on insulin sensitivity and the systemic inflammatory response in human subjects. *Br J Nutr*. 2010;**104**(12):1831-8. [PubMed ID: 20815975]. <https://doi.org/10.1017/S0007114510002874>.
23. Kumar S, Kumar R, Rohilla L, Jacob N, Yadav J, Sachdeva N. A high potency multi-strain probiotic improves glycemic control in children with new-onset type 1 diabetes mellitus: A randomized, double-blind, and placebo-controlled pilot study. *Pediatr Diabetes*. 2021;**22**(7):1014-22. [PubMed ID: 34174128]. <https://doi.org/10.1111/pedi.13244>.
24. Stewart CJ, Ajami NJ, O'Brien JL, Hutchinson DS, Smith DP, Wong MC, et al. Temporal development of the gut microbiome in early childhood from the TEDDY study. *Nature*. 2018;**562**(7728):583-8. [PubMed ID: 30356187]. [PubMed Central ID: PMC6415775]. <https://doi.org/10.1038/s41586-018-0617-x>.
25. Asemi Z, Zare Z, Shakeri H, Sabihi SS, Esmailzadeh A. Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in patients with type 2 diabetes. *Ann Nutr Metab*. 2013;**63**(1-2):1-9. [PubMed ID: 23899653]. <https://doi.org/10.1159/000349922>.
26. Yadav H, Jain S, Sinha PR. Effect of skim milk and dahi (yogurt) on blood glucose, insulin, and lipid profile in rats fed with high fructose diet. *J Med Food*. 2006;**9**(3):328-35. [PubMed ID: 17004894]. <https://doi.org/10.1089/jmf.2006.9.328>.
27. Yadav H, Jain S, Sinha PR. Oral administration of dahi containing probiotic *Lactobacillus acidophilus* and *Lactobacillus casei* delayed the progression of streptozotocin-induced diabetes in rats. *J Dairy Res*. 2008;**75**(2):189-95. [PubMed ID: 18474136]. <https://doi.org/10.1017/S0022029908003129>.